Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes

Author： Grieve Stuart M   Ansquer Jean-Claude   Keech Anthony C  

Publisher： Future Medicine

ISSN： 1479-6678

Source： Future Cardiology, Vol.2, Iss.6, 2006-11, pp. : 635-646

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD

By  

Current Cardiology Reviews, Vol. 6, Iss. 2, 2010-05 ,pp. : 112-118

Bentham Science Publishers

Access to resources Recommend Favorite

Cardiovascular Disease Risk of Type 2 Diabetes Mellitus and Metabolic Syndrome: Focus on Aggressive Management of Dyslipidemia

By  

Current Diabetes Reviews, Vol. 1, Iss. 2, 2005-06 ,pp. : 127-135

Bentham Science Publishers

Access to resources Recommend Favorite

A New Perspective in the Treatment of Dyslipidemia: Can Fenofibrate Offer Unique Benefits in the Treatment of Type 2 Diabetes Mellitus?

By Steiner George  

Treatments in Endocrinology, Vol. 4, Iss. 5, 2005-01 ,pp. : 311-317

Adis International

Access to resources Recommend Favorite

Carbohydrate restriction as the default treatment for type 2 diabetes and metabolic syndrome

By Feinman Richard   Volek Jeff  

Scandinavian Cardiovascular Journal, Vol. 42, Iss. 4, 2008-01 ,pp. : 256-263

Informa Healthcare

Access to resources Recommend Favorite

The Metabolic Syndrome and Type 2 Diabetes: Epidemiological Figures and Country Specificities

By  

Cerebrovascular Diseases, Vol. 20, Iss. 1, 2005-11 ,pp. : 2-8

Karger

Access to resources Recommend Favorite